| Identification | Back Directory | [Name]
ABT-510 | [CAS]
251579-55-2 | [Synonyms]
ABT-510
ABT-510 TFA salts
RIWLPSIAFBLILR-CPCUXHMXSA-N | [Molecular Formula]
C46H83N13O11 | [MDL Number]
MFCD25976608 | [MOL File]
251579-55-2.mol | [Molecular Weight]
994.23 |
| Hazard Information | Back Directory | [Uses]
ABT-510 is an anti-angiogenic TSP peptide (Thrombospondin-1 analogue) that induces apoptosis and inhibits ovarian tumour growth in an orthotopic, syngeneic model of epithelial ovarian cancer. ABT-510 also reduces angiogenesis and inflammatory responses in a murine model of inflammatory bowel disease. ABT-510 can be used in studies of cancer (particularly epithelial ovarian cancer) and inflammatory bowel disease (IBD)[1][2]. | [in vivo]
ABT-510 (100 mg/kg; i.p.; single daily for 90 days) induces cells apoptosisin vivo and leads to a significant reduction in epithelial ovarian tumor size, ascites fluid volume, and secondary lesion dissemination in mice[1].
ABT-510 (60 mg/kg; osmotic minipumps for s.c.; single daily for 7 days) decreases angiogenesis and inflammation in a murine model of inflammatory bowel disease[2]. | Animal Model: | TSP-1-Null mice (C57BL/6 background; orthotopic, syngeneic model of epithelial ovarian cancer)[1]. | | Dosage: | 100 mg/kg | | Administration: | Intraperitoneal injection; single daily for 90 days | | Result: | Reduced ovarian tumor growth in wild-type and TSP-1-Null Mice.
Significantly reduced the volume of ascites and completely abolished the formation of peritoneal lesions.
Reversed ovarian tumor hypervascularization and increased the proportion of mature blood vessels.
|
| Animal Model: | TSP-1-Null mice (C57BL/6 background; 6-week-old; DSS-induced inflammatory bowel disease murine model)[2]. | | Dosage: | 60 mg/kg | | Administration: | Subcutaneously implanted osmotic minipumps (0.5μL/h); single daily for 7 days | | Result: | Significantly delayed DSS-induced bleeding and improved the overall severity of disease.
Significantly diminished inflammation grading and angiogenesis
|
| [References]
[1] Greenaway J, et al. ABT-510 induces tumor cell apoptosis and inhibits ovarian tumor growth in an orthotopic, syngeneic model of epithelial ovarian cancer. Mol Cancer Ther. 2009 Jan;8(1):64-74. DOI:10.1158/1535-7163.MCT-08-0864
[2] Punekar S, et al. Thrombospondin 1 and its mimetic peptide ABT-510 decrease angiogenesis and inflammation in a murine model of inflammatory bowel disease. Pathobiology. 2008;75(1):9-21. DOI:10.1159/000113790
[3] Isenberg JS, et.al. Differential effects of ABT-510 and a CD36-binding peptide derived from the type 1 repeats of thrombospondin-1 on fatty acid uptake, nitric oxide signaling, and caspase activation in vascular cells. Biochem Pharmacol. 2008 Feb 15;75(4):875-82. DOI:10.1016/j.bcp.2007.10.025 |
|
| Company Name: |
InvivoChem
|
| Tel: |
13549236410 |
| Website: |
https://www.invivochem.cn/ |
| Company Name: |
YantaiBio
|
| Tel: |
13758194781 |
| Website: |
|
| Company Name: |
Fuan Bio
|
| Tel: |
15002819872 |
| Website: |
|
|